Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106625 · ClinicalTrials.gov registry record · Phase 3
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 469
- Enrollment target
NCT01106625: Completed Phase 3 study, sponsored by Janssen Research & Development.
NCT01106625 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 469 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01106625, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 469 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
Primary Outcome
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Canagliflozin
- DRUG Sulphonylruea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
What the finished NCT01106625 record still lists
NCT01106625 is an interventional study that assigns participants to a tested intervention. The registered 469 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01106625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01106625 about?
NCT01106625 is a clinical study titled "The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)". The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
What is the current status of trial NCT01106625?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 469 participants. The study started on 2010-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01106625?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Canagliflozin (DRUG), Sulphonylruea (DRUG).
Who is sponsoring clinical trial NCT01106625?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01106625's enrollment target sits among peer trials
469 815th of 2000 higher than 1,185 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia